论文部分内容阅读
有关对强心甙的药代动力学的研究,早在50—60年代就开始,但由于该药在体内含量甚微,目前尚无特别灵敏的定量测定方法,因此在临床上还存在许多问题。例如:关于洋地黄毒甙的主要代谢产物——双氢洋地黄毒甙(Dihydrodigitoxin)的生成过程还不很清楚。 Boden博士,近年来曾成功地采用气相色层法及质谱法对多种药物的微量代谢物进行定量测定,同时对健康人以及有肾功能障碍的患者血中的洋地黄毒甙及其代
Studies on the pharmacokinetics of cardiac glycosides started in the 1950s and 1960s, but due to the small amount of the drug in the body, there is currently no specific and sensitive method for quantitative determination. Therefore, there are still many clinical problems . For example, the generation of dihydrodigitoxin, the major metabolite of digoxigenin, is not well understood. Dr. Boden, in recent years has successfully used gas chromatography and mass spectrometry for the quantitative determination of trace metabolites of various drugs, while digoxin and its generation in the blood of healthy people and patients with renal dysfunction